Methodology
Entries to the Life Sciences Investment Tracker are based on data from SEC filings, quarterly earnings reports, and company announcements, updated quarterly.
The data encompass several types of announcements categorized as follows:
Discontinued Drug
Cessation of research for a drug candidate, excluding those halted for safety, efficacy, or clinical reasons. Drug candidates must either be referenced by name or as an unnamed drug candidate for a specified disease or condition.
Discontinued Research
Cessation of research for a drug candidate or broader program, excluding those halted for safety, efficacy, or clinical reasons.
Layoffs
Reduction in company workforce.
Negative Outlook
Reference to the Inflation Reduction Act as having a negative impact on the company or industry's ability to research new treatments or successfully bring them to market.
Neutral Outlook
Reference to the Inflation Reduction Act as having an uncertain impact on the company or industry's ability to research new treatments or successfully bring them to market.
The data encompass several types of announcements categorized as follows:
Discontinued Drug
Cessation of research for a drug candidate, excluding those halted for safety, efficacy, or clinical reasons. Drug candidates must either be referenced by name or as an unnamed drug candidate for a specified disease or condition.
Discontinued Research
Cessation of research for a drug candidate or broader program, excluding those halted for safety, efficacy, or clinical reasons.
Layoffs
Reduction in company workforce.
Negative Outlook
Reference to the Inflation Reduction Act as having a negative impact on the company or industry's ability to research new treatments or successfully bring them to market.
Neutral Outlook
Reference to the Inflation Reduction Act as having an uncertain impact on the company or industry's ability to research new treatments or successfully bring them to market.
Each entry is categorized by disease area and drug type:
Disease Area
For 'Discontinued Drug' or 'Discontinued Research' entries, this category reflects specific drug candidates or research programs. For other entries, it reflects the company's primary research focus, unless otherwise stated in the company's announcement.
Drug Type
For 'Discontinued Drug' entries, this category specifies whether the drug candidates are biologics or small molecules. For other entries, it lists both biologics and small molecules, unless otherwise stated in the company's announcement.
The tracker also features two counters:
Drugs Discontinued
Tallies each named or unnamed drug candidate referenced in 'Discontinued Drug' entries. For example, if a company references 4 discontinued drug candidates in 1 public announcement, all 4 drugs are reflected in the tally.
Research Programs
Tallies each drug candidate or broader research program referenced in 'Discontinued Research' entries. This counter reflects a conservative estimate, since it's possible that some discontinued research programs may impact multiple drug candidates.
